95 related articles for article (PubMed ID: 1869097)
1. Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma.
Markman M; Rothman R; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Hoskins W
Gynecol Oncol; 1991 Jun; 41(3):217-9. PubMed ID: 1869097
[TBL] [Abstract][Full Text] [Related]
2. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman M; Rothman R; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Lewis JL
J Clin Oncol; 1991 Mar; 9(3):389-93. PubMed ID: 1999708
[TBL] [Abstract][Full Text] [Related]
3. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer.
Markmann M; Rothman R; Reichman B; Hakes T; Lewis JL; Rubin S; Jones W; Almadrones L; Hoskins W
J Cancer Res Clin Oncol; 1991; 117(2):89-90. PubMed ID: 2007614
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
5. Long-term evolution of renal function in patients with ovarian cancer after whole abdominal irradiation with or without preceding cisplatin.
Schneider DP; Marti HP; Von Briel C; Frey FJ; Greiner RH
Ann Oncol; 1999 Jun; 10(6):677-83. PubMed ID: 10442190
[TBL] [Abstract][Full Text] [Related]
6. Measures of renal function in patients with cisplatin-related chronic renal disease.
Reed E; Jacob J; Brawley O
J Natl Med Assoc; 1991 Jun; 83(6):522-6. PubMed ID: 1865503
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.
Rubin SC; Hoskins WJ; Saigo PE; Chapman D; Hakes TB; Markman M; Reichman B; Almadrones L; Lewis JL
Gynecol Oncol; 1991 Aug; 42(2):137-41. PubMed ID: 1894172
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
11. Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamide are equally effective in second line intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Sznurkowski J; Emerich J
Adv Med Sci; 2012 Jun; 57(1):46-50. PubMed ID: 22430042
[TBL] [Abstract][Full Text] [Related]
12. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen.
Bolis G; Scarfone G; Luchini L; Ferraris C; Zanaboni F; Presti M; Giardina G; Villa A; Parazzini F
Eur J Cancer; 1994; 30A(12):1764-8. PubMed ID: 7880602
[TBL] [Abstract][Full Text] [Related]
13. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
14. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV; Iasonos A; Herr H; Donat SM
J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
Piver MS; Recio FO; Baker TR; Driscoll D
Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
17. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
18. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
[TBL] [Abstract][Full Text] [Related]
19. [Impact of first-line chemotherapy on renal function in patients with advanced upper tract urothelial carcinoma].
Li X; Sheng XN; Chi ZH; Cui CL; Si L; Mao LL; Tang BX; Lian B; Wang X; Yan XQ; Li SM; Bai X; Zhou L; Kong Y; Dai J; Guo J
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2574-2578. PubMed ID: 30220142
[No Abstract] [Full Text] [Related]
20. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
